[Skip to Content]
[Skip to Content Landing]
June 2007

The Current Status of Evaluation and Treatment of High-Risk Cutaneous MelanomaTherapeutic Breakthroughs Remain Elusive

Arch Dermatol. 2007;143(6):785-787. doi:10.1001/archderm.143.6.785

In this month's ARCHIVES, González1 and Tsai2 provide evidence-based critiques of 2 recently published articles regarding cutaneous melanoma. These articles evaluate the clinical utility of sentinel node biopsies (SNBs) and systemic therapy for patients with high-risk melanoma. Both topics have generated much discourse over the past decade, as until recently, “standards of care” have been dictated by theories and consensus owing to the lack of good evidence.

First Page Preview View Large
First page PDF preview
First page PDF preview